New research has identified a treatment for metastatic renal cell cancer that is more effective and better tolerated in the recovery of those patients. According to UPI online, the new drug known as nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits across the board in patients with metastatic renal cell cancer. Annually there are 338,000 patients diagnosed with mRCC. The study, was published in the July edition of the Journal of Clinical Oncology.
This video was produced by YT Wochit News using http://wochit.com